BWM
CLLS

Baystate Wealth Management’s Cellectis CLLS Stock Holding History

Baystate Wealth Management’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$1.54K Buy
+500
New +$1.19K ﹤0.01% 1107

Other funds holding CLLS

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Baystate Wealth Management's CLLS Position: Q4 2023 in Review

Baystate Wealth Management opened a new position in Cellectis (CLLS) in Q4 2023: 500 shares worth $1.54K. The stake represents ﹤0.01% of the portfolio and ranks #1107 among its holdings.

34 funds tracked by Wall St. Rank hold CLLS as of Q4 2023.

  • Baystate Wealth Management held 500 shares of Cellectis worth $1.54K as of Q4 2023.
  • Cellectis was a new Baystate Wealth Management position in Q4 2023.
  • Cellectis made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #1107 holding.
  • 34 funds tracked by Wall St. Rank held Cellectis as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.